Biomerica, Inc.

BMRA Healthcare Medical Devices

Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025. In the quarter to May 2026, revenue grew 17.0%, EPS grew 37.8% and free cash flow fell 35.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

1.85 0.03 −1.60%
Market cap
$8.6M
P/E
0.0×
Fwd P/E
11.4×
Dividend yield
—
F-score
4/9
Altman Z
−12.45
Beneish M
−2.06
Dividend safety
n/a
Older periods Aug '25 Nov '25 Feb '26 May '26
Piotroski F-Score

+8 more TTM periods

6 4 3 4
ROE
(69.61%) (84.30%) (94.32%) (112.10%)
ROA
(49.65%) (60.49%) (68.12%) (59.43%)
ROIC
(145.31%) (173.99%) (168.95%) (251.51%)
Return on Tangible Assets
(84.49%) (108.87%) (157.33%) (234.04%)
Average Days of Receivables
90.05 77.54 79.40 64.34
Free Cash Flow per Share
(1.05) (1.02) (1.07) (1.18)
Free Cash Flow
(2.77) (2.97) (3.23) (3.43)
Other line items

Show all line items

Columns are period end dates